• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对猴免疫缺陷病毒SIVmne包膜和核心抗原的免疫反应在猕猴抵抗同源克隆和未克隆病毒攻击中的作用。

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

作者信息

Polacino P S, Stallard V, Klaniecki J E, Pennathur S, Montefiori D C, Langlois A J, Richardson B A, Morton W R, Benveniste R E, Hu S L

机构信息

Regional Primate Research Center, University of Washington, Seattle, USA.

出版信息

J Virol. 1999 Oct;73(10):8201-15. doi: 10.1128/JVI.73.10.8201-8215.1999.

DOI:10.1128/JVI.73.10.8201-8215.1999
PMID:10482571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC112838/
Abstract

We previously showed that envelope (gp160)-based vaccines, used in a live recombinant virus priming and subunit protein boosting regimen, protected macaques against intravenous and intrarectal challenges with the homologous simian immunodeficiency virus SIVmne clone E11S. However, the breadth of protection appears to be limited, since the vaccines were only partially effective against intravenous challenge by the uncloned SIVmne. To examine factors that could affect the breadth and the efficacy of this immunization approach, we studied (i) the effect of priming by recombinant vaccinia virus; (ii) the role of surface antigen gp130; and (iii) the role of core antigens (Gag and Pol) in eliciting protective immunity. Results indicate that (i) priming with recombinant vaccinia virus was more effective than subunit antigen in eliciting protective responses; (ii) while both gp130 and gp160 elicited similar levels of SIV-specific antibodies, gp130 was not as effective as gp160 in protection, indicating a possible role for the transmembrane protein in presenting functionally important epitopes; and (iii) although animals immunized with core antigens failed to generate any neutralizing antibody and were infected upon challenge, their virus load was 50- to 100-fold lower than that of the controls, suggesting the importance of cellular immunity or other core-specific immune responses in controlling acute infection. Complete protection against intravenous infection by the pathogenic uncloned SIVmne was achieved by immunization with both the envelope and the core antigens. These results indicate that immune responses to both antigens may contribute to protection and thus argue for the inclusion of multiple antigens in recombinant vaccine designs.

摘要

我们先前表明,基于包膜(gp160)的疫苗,采用重组活病毒初免和亚单位蛋白加强免疫方案,可保护猕猴免受同源猴免疫缺陷病毒SIVmne克隆E11S的静脉内和直肠内攻击。然而,保护的广度似乎有限,因为这些疫苗对未克隆的SIVmne的静脉内攻击仅部分有效。为了研究可能影响这种免疫方法的广度和效力的因素,我们研究了:(i)重组痘苗病毒初免的效果;(ii)表面抗原gp130的作用;以及(iii)核心抗原(Gag和Pol)在引发保护性免疫中的作用。结果表明:(i)重组痘苗病毒初免在引发保护性反应方面比亚单位抗原更有效;(ii)虽然gp130和gp160诱导的SIV特异性抗体水平相似,但gp130在保护方面不如gp160有效,表明跨膜蛋白在呈递功能重要表位方面可能发挥作用;以及(iii)尽管用核心抗原免疫的动物未能产生任何中和抗体且在攻击后被感染,但其病毒载量比对照组低50至100倍,这表明细胞免疫或其他核心特异性免疫反应在控制急性感染中很重要。通过用包膜抗原和核心抗原免疫,可实现对致病性未克隆SIVmne静脉内感染的完全保护。这些结果表明,对两种抗原的免疫反应可能有助于提供保护,因此支持在重组疫苗设计中纳入多种抗原。

相似文献

1
Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.针对猴免疫缺陷病毒SIVmne包膜和核心抗原的免疫反应在猕猴抵抗同源克隆和未克隆病毒攻击中的作用。
J Virol. 1999 Oct;73(10):8201-15. doi: 10.1128/JVI.73.10.8201-8215.1999.
2
Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines.用重组猴免疫缺陷病毒SIVmne gp160疫苗联合免疫方案保护猕猴免受直肠内感染。
J Virol. 1999 Apr;73(4):3134-46. doi: 10.1128/JVI.73.4.3134-3146.1999.
3
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.在联合免疫方案中,猿猴免疫缺陷病毒SIVmne gp160疫苗引发的保护性免疫广度有限。
J Virol. 1999 Jan;73(1):618-30. doi: 10.1128/JVI.73.1.618-630.1999.
4
Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection.重组亚单位疫苗作为一种研究针对灵长类慢病毒感染的保护性相关因素的方法。
Immunol Lett. 1996 Jun;51(1-2):115-9. doi: 10.1016/0165-2478(96)02564-3.
5
Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.通过重组痘苗病毒和SIVmne gp160联合免疫接种,保护经痘苗病毒预处理的猕猴免受SIVmne感染。
J Med Primatol. 1993 Feb-May;22(2-3):92-9.
6
Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.表达猿猴免疫缺陷病毒(SIV)Gag-Pol和/或Env的重组改良安卡拉痘苗病毒在感染致病性SIV的猕猴中的比较疗效。
J Virol. 2000 Mar;74(6):2740-51. doi: 10.1128/jvi.74.6.2740-2751.2000.
7
Protection from pathogenic SIV challenge using multigenic DNA vaccines.使用多基因DNA疫苗抵御致病性猴免疫缺陷病毒攻击
Immunol Lett. 1999 Mar;66(1-3):183-8. doi: 10.1016/s0165-2478(98)00156-4.
8
Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles.用产生病毒样颗粒的多基因DNA疫苗对猕猴进行接种所引发的针对猴免疫缺陷病毒攻击的保护性免疫。
AIDS Res Hum Retroviruses. 2004 Apr;20(4):425-34. doi: 10.1089/088922204323048177.
9
Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.通过具有复制能力的Ad5hr-SIVenv/rev和Ad5hr-SIVgag重组初免/gp120加强方案,增强恒河猴对直肠内猿猴免疫缺陷病毒SIV(mac251)攻击的保护作用。
J Virol. 2003 Aug;77(15):8354-65. doi: 10.1128/jvi.77.15.8354-8365.2003.
10
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.用包裹在纳米颗粒中的Toll样受体配体辅助猿猴免疫缺陷病毒疫苗可诱导持续性抗体反应并增强对TRIM5α限制型猕猴的保护。
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.

引用本文的文献

1
Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study.HIV 病毒毒力对疾病修正性疫苗的响应演变:建模研究。
Vaccine. 2023 Oct 13;41(43):6461-6469. doi: 10.1016/j.vaccine.2023.08.071. Epub 2023 Sep 14.
2
Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.用重组痘苗病毒初免和肌肉注射蛋白加强进行口服免疫可保护猕猴免受直肠内猿猴-人类免疫缺陷病毒攻击。
Clin Vaccine Immunol. 2015 Dec 30;23(3):204-12. doi: 10.1128/CVI.00597-15.
3
Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.黏膜疫苗:用于控制黏膜部位病原体和肿瘤的新策略与应用
Hum Vaccin Immunother. 2014;10(8):2175-87. doi: 10.4161/hv.29269.
4
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.针对C组猿猴-人免疫缺陷病毒嵌合体的多模态疫苗接种:对异源2级病毒黏膜攻击的部分保护作用
Vaccine. 2014 Nov 12;32(48):6527-36. doi: 10.1016/j.vaccine.2014.08.065. Epub 2014 Sep 20.
5
Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.艾滋病疫苗研究中非人类灵长类动物模型的教训:从雷区到里程碑。
Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007310. doi: 10.1101/cshperspect.a007310.
6
Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection.双模态艾滋病疫苗方法:诱导细胞和体液免疫可以预防系统性感染。
Vaccine. 2010 May 26;28 Suppl 2(0 2):B25-31. doi: 10.1016/j.vaccine.2009.10.131.
7
Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.用表达猿猴免疫缺陷病毒包膜的改良安卡拉痘苗病毒重组体免疫的恒河猴生存率提高,这与记忆性CD4 + T细胞损失减少和中和抗体滴度升高相关。
J Virol. 2009 Jun;83(11):5388-400. doi: 10.1128/JVI.02598-08. Epub 2009 Mar 25.
8
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood.用肽脉冲血液对感染SIV的猕猴进行免疫治疗后对病毒血症的控制及艾滋病的预防
PLoS Pathog. 2008 May 2;4(5):e1000055. doi: 10.1371/journal.ppat.1000055.
9
DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.在猕猴受到X4 SHIV攻击后,DNA-MVA疫苗的保护作用与攻击当天抗病毒CD4 + 细胞介导的免疫水平以及攻击后CD4 + T细胞记忆的保存相关。
AIDS Res Hum Retroviruses. 2008 Mar;24(3):505-19. doi: 10.1089/aid.2007.0191.
10
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.去除人类免疫缺陷病毒1型gp120中的单个N-连接聚糖会增强诱导中和抗体反应的能力。
J Virol. 2008 Jan;82(2):638-51. doi: 10.1128/JVI.01691-07. Epub 2007 Oct 24.

本文引用的文献

1
Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines.用重组猴免疫缺陷病毒SIVmne gp160疫苗联合免疫方案保护猕猴免受直肠内感染。
J Virol. 1999 Apr;73(4):3134-46. doi: 10.1128/JVI.73.4.3134-3146.1999.
2
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.针对HIV-1包膜糖蛋白的中和抗体能够完全阻断猕猴的HIV-1/SIV嵌合病毒感染。
Nat Med. 1999 Feb;5(2):204-10. doi: 10.1038/5568.
3
Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques.减毒活、多次缺失的猿猴免疫缺陷病毒可导致幼年和成年猕猴患艾滋病。
Nat Med. 1999 Feb;5(2):194-203. doi: 10.1038/5557.
4
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1.感染了 nef 缺失型 HIV-1 的个体中 CD4 T 细胞计数下降。
N Engl J Med. 1999 Jan 21;340(3):236-7. doi: 10.1056/NEJM199901213400314.
5
Fusion-competent vaccines: broad neutralization of primary isolates of HIV.具有融合能力的疫苗:对HIV原代分离株的广泛中和作用。
Science. 1999 Jan 15;283(5400):357-62. doi: 10.1126/science.283.5400.357.
6
Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development.攻毒前高中和抗体以及对gp41的持久免疫反应性与恒河猴抵御猿猴免疫缺陷病毒感染或疾病发展的保护作用相关。
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):441-50. doi: 10.1097/00042560-199812150-00002.
7
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.在联合免疫方案中,猿猴免疫缺陷病毒SIVmne gp160疫苗引发的保护性免疫广度有限。
J Virol. 1999 Jan;73(1):618-30. doi: 10.1128/JVI.73.1.618-630.1999.
8
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.推进AIDSVAX至3期。安全性、免疫原性及3期计划。
AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31.
9
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.针对一种异源、非诱导合胞体的原发性人类免疫缺陷病毒的疫苗保护作用。
J Virol. 1998 Dec;72(12):10275-80. doi: 10.1128/JVI.72.12.10275-10280.1998.
10
Macaques infected with cloned simian immunodeficiency virus show recurring nef gene alterations.感染克隆猿猴免疫缺陷病毒的猕猴出现反复的nef基因改变。
Virology. 1998 Sep 30;249(2):260-74. doi: 10.1006/viro.1998.9325.